Versant Venture Management, LLC 13F holdings
Versant Venture Management, LLC reported 8 positions with a total reported value of $162.6M as of 2026-06-30, in its 13F for Q2 2026, filed 2026-08-12. Top holdings by reported value: GLUE Monte Rosa Therapeutics, Inc. (47.3%), IPSC Century Therapeutics, Inc. (18.3%), JBIO Jade Biosciences, Inc. (13.6%), LENZ Lenz Therapeutics, Inc. (9.3%), CTNM Contineum Therapeutics, Inc. (5.5%). Against 2026-03-31 it opened 0 new positions and exited 0. Next 13F due by 2026-11-14, the legal deadline 45 days after the quarter ending 2026-09-30.
Email me when Versant Venture Management, LLC files its 13F
A free account follows up to 10 funds. New 13F filings arrive in your daily or weekly digest. No password and no card.
Top holdings
| Holding | Shares | Reported value | % of portfolio |
|---|---|---|---|
| GLUE Monte Rosa Therapeutics, Inc. | 3,180,780 | $77.0M | 47.3% |
| IPSC Century Therapeutics, Inc. | 12,166,109 | $29.8M | 18.3% |
| JBIO Jade Biosciences, Inc. | 991,783 | $22.0M | 13.6% |
| LENZ Lenz Therapeutics, Inc. | 2,656,888 | $15.1M | 9.3% |
| CTNM Contineum Therapeutics, Inc. | 542,628 | $8.9M | 5.5% |
| CRSP CRISPR Therapeutics AG | 148,831 | $8.1M | 5.0% |
| SKYE Skye Bioscience, Inc. | 2,007,704 | $1.4M | 0.9% |
| TPST Tempest Therapeutics, Inc. | 269,772 | $299.4K | 0.2% |
New positions this quarter
No new positions.
Sold out
No positions were sold out.
Biggest increases and decreases
Increases
No position was increased.
Decreases
| Holding | Shares 2026-03-31 | Shares 2026-06-30 | Change | Reported value |
|---|---|---|---|---|
| JBIO Jade Biosciences, Inc. | 1,525,820 | 991,783 | -35.0% | $22.0M |
